Evidence map›Paper›PMID 25520503›Full record

ArticleJournal of virology2015

COMMD1/Murr1 reinforces HIV-1 latent infection through IκB-α stabilization.

Manabu Taura, Eriko Kudo, Ryusho Kariya, Hiroki Goto, Kouki Matsuda, Shinichiro Hattori, Kulthida Vaeteewoottacharn, Fiona McDonald, Mary Ann Suico, Tsuyoshi Shuto and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. APOBEC3A regulates transcription from interferon-stimulated response elements.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. The mTOR Complex Controls HIV Latency.Cell host & microbe · 2016
    Article
  9. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Manabu TauraDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Eriko KudoDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Ryusho KariyaDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Hiroki GotoDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Kouki MatsudaDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Shinichiro HattoriDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Kulthida VaeteewoottacharnDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Fiona McDonaldDepartment of Physiology, University of Otago, Dunedin, New Zealand.
Mary Ann SuicoDepartment of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Tsuyoshi ShutoDepartment of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Hirofumi KaiDepartment of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Seiji OkadaDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan okadas@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0003-3124-5206
Kumamoto University · JPUniversity of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe transcription factor NF-κB is important for HIV-1 transcription initiation in primary HIV-1 infection and reactivation in latently HIV-1-infected cells. However, comparative analysis of the regulation and function of NF-κB in latently HIV-1-infected cells has not been done. Here we show that the expression of IκB-α, an endogenous inhibitor of NF-κB, is enhanced by latent HIV-1 infection via induction of the host-derived factor COMMD1/Murr1 in myeloid cells but not in lymphoid cells by using four sets of latently HIV-1-infected cells and the respective parental cells. IκB-α protein was stabilized by COMMD1, which attenuated NF-κB signaling during Toll-like receptor ligand and tumor necrosis factor alpha treatment and enhanced HIV-1 latency in latently HIV-1-infected cells. Activation of the phosphoinositol 3-kinase (PI3K)-JAK pathway is involved in COMMD1 induction in latently HIV-1-infected cells. Our findings indicate that COMMD1 induction is the NF-κB inhibition mechanism in latently HIV-1-infected cells that contributes to innate immune deficiency and reinforces HIV-1 latency. Thus, COMMD1 might be a double-edged sword that is beneficial in primary infection but not beneficial in latent infection when HIV-1 eradication is considered. IMPORTANCE: HIV-1 latency is a major barrier to viral eradication in the era of combination antiretroviral therapy. In this study, we found that COMMD1/Murr1, previously identified as an HIV-1 restriction factor, inhibits the proteasomal degradation of IκB-α by increasing the interaction with IκB-α in latently HIV-1-infected myeloid cells. IκB-α protein was stabilized by COMMD1, which attenuated NF-κB signaling during the innate immune response and enhanced HIV-1 latency in latently HIV-1-infected cells. Activation of the PI3K-JAK pathway is involved in COMMD1 induction in latently HIV-1-infected cells. Thus, the host-derived factor COMMD1 is beneficial in suppressing primary infection but enhances latent infection, indicating that it may be a double-edged sword in HIV-1 eradication.

Indexed as

Host-Pathogen InteractionsVirus LatencyAdaptor Proteins, Signal TransducingCell LineHIV-1HumansI-kappa B ProteinsNF-KappaB Inhibitor alphaAdaptor Proteins, Signal TransducingCOMMD1 protein, humanI-kappa B ProteinsNF-KappaB Inhibitor alphaNFKBIA protein, human

Identifiers

PMID25520503
PMCPMC4325709
OpenAlexW2001326834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.